Physician profile
Michael M Dee
NPI 1053302182
$2,481.38
in general payments reported to CMS, 2019-2025
31 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $390 · 2021: $116 · 2022: $473 · 2023: $293 · 2024: $148 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $443.39 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $414.74 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $261.05 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.60 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $148.29 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $128.38 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.33 | 2019-2023 | Eliquis |
| Amgen INC. | $79.47 | 2019 | |
| Glaxosmithkline, LLC. | $64.39 | 2019-2023 | Arexvy |
| Astellas Pharma US INC | $56.12 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $52.19 | 2019 | |
| Dexcom, INC. | $41.80 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $37.76 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $35.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $35.38 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.49 | 2023 | Rexulti |
| Abbvie INC. | $30.41 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $28.00 | 2019-2020 | |
| Orthofix Medical, INC. | $26.74 | 2023 | Physio-Stim |
| Merck Sharp & Dohme LLC | $23.55 | 2019-2020 | |
| Allergan, INC. | $23.08 | 2019 | |
| Mylan Specialty L.P. | $21.27 | 2020 | |
| Alnylam Pharmaceuticals INC. | $17.57 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.83 | 2020 | |
| Lundbeck LLC | $16.63 | 2025 | Rexulti |
| Gilead Sciences, INC. | $16.38 | 2019 | |
| Philips North America LLC | $15.77 | 2019 | |
| Grifols USA, LLC | $14.66 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.71 | 2025 | Rexulti |
| Medtronic, INC. | $11.72 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.